Literature DB >> 21664855

Serotonin and dopamine striatal innervation in Parkinson's disease and Huntington's chorea.

Catherine Bédard1, Marie-Josée Wallman, Emmanuelle Pourcher, Peter V Gould, André Parent, Martin Parent.   

Abstract

In contrast to our vast knowledge of the dopamine (DA) system, much less is known about the involvement of serotonin (5-HT) in neurodegenerative diseases affecting the basal ganglia. Therefore, we designed a study that aimed at characterizing the status of the striatal DA and 5-HT systems in patients who suffered from either Parkinson's (PD) or Huntington's disease (HD), compared to age-matched controls. Antibodies against tyrosine hydroxylase (TH) and 5-HT transporter (SERT) were used as markers of DA and 5-HT axonal profiles, respectively. The density and pattern of TH+ and SERT + innervation were determined by optical density measurements as well as by direct stereological estimates of labeled axon varicosities. The results reveal a significant decrease in TH immunoreactivity and TH + axon terminals throughout the striatum in both PD and HD, whereas the intensity of SERT immunostaining and the density of SERT + axon varicosities were found to be slightly increased in the striatum of PD and HD patients compared to controls. These findings reveal that the nigrostriatal DA system is significantly impaired in both PD and HD compared to the striatal 5-HT innervation, which is slightly increased in these two conditions. The striatal 5-HT augmentation observed in PD might be the result of a neural mechanism designed to compensate for DA denervation, whereas the marked atrophy of the striatum might explain the increase in the 5-HT innervation noted in HD. These findings underline the importance of the complex interplay between DA and 5-HT striatal afferents in the elaboration of appropriate motor behaviour.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21664855     DOI: 10.1016/j.parkreldis.2011.05.012

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  32 in total

Review 1.  Dopamine Receptors and Neurodegeneration.

Authors:  Claudia Rangel-Barajas; Israel Coronel; Benjamín Florán
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

2.  Reduced vesicular monoamine transport disrupts serotonin signaling but does not cause serotonergic degeneration.

Authors:  Shawn P Alter; Kristen A Stout; Kelly M Lohr; Tonya N Taylor; Kennie R Shepherd; Minzheng Wang; Thomas S Guillot; Gary W Miller
Journal:  Exp Neurol       Date:  2015-09-30       Impact factor: 5.330

3.  Human-specific increase of dopaminergic innervation in a striatal region associated with speech and language: A comparative analysis of the primate basal ganglia.

Authors:  Mary Ann Raghanti; Melissa K Edler; Alexa R Stephenson; Lakaléa J Wilson; William D Hopkins; John J Ely; Joseph M Erwin; Bob Jacobs; Patrick R Hof; Chet C Sherwood
Journal:  J Comp Neurol       Date:  2015-12-29       Impact factor: 3.215

4.  Thymoquinone loaded solid lipid nanoparticles counteracts 3-Nitropropionic acid induced motor impairments and neuroinflammation in rat model of Huntington's disease.

Authors:  Surekha Ramachandran; Sumathi Thangarajan
Journal:  Metab Brain Dis       Date:  2018-05-31       Impact factor: 3.584

5.  Modification of spectral features by nonhuman primates.

Authors:  Daniel J Weiss; Cara F Hotchkin; Susan E Parks
Journal:  Behav Brain Sci       Date:  2014-12       Impact factor: 12.579

6.  Class-IIa Histone Deacetylase Inhibition Promotes the Growth of Neural Processes and Protects Them Against Neurotoxic Insult.

Authors:  Louise M Collins; Luc J Adriaanse; Surabhi D Theratile; Shane V Hegarty; Aideen M Sullivan; Gerard W O'Keeffe
Journal:  Mol Neurobiol       Date:  2014-07-29       Impact factor: 5.590

Review 7.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 8.  Brain dopamine neurone 'damage': methamphetamine users vs. Parkinson's disease - a critical assessment of the evidence.

Authors:  Stephen J Kish; Isabelle Boileau; Russell C Callaghan; Junchao Tong
Journal:  Eur J Neurosci       Date:  2016-09-05       Impact factor: 3.386

9.  Serotonin hyperinnervation and upregulated 5-HT2A receptor expression and motor-stimulating function in nigrostriatal dopamine-deficient Pitx3 mutant mice.

Authors:  Li Li; Guozhen Qiu; Shengyuan Ding; Fu-Ming Zhou
Journal:  Brain Res       Date:  2012-11-15       Impact factor: 3.252

Review 10.  The role of dopamine in Huntington's disease.

Authors:  Carlos Cepeda; Kerry P S Murphy; Martin Parent; Michael S Levine
Journal:  Prog Brain Res       Date:  2014       Impact factor: 2.453

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.